WO1994018988A3 - Use of heparins for the treatment of inflammatory or immunological diseases - Google Patents

Use of heparins for the treatment of inflammatory or immunological diseases Download PDF

Info

Publication number
WO1994018988A3
WO1994018988A3 PCT/EP1994/000506 EP9400506W WO9418988A3 WO 1994018988 A3 WO1994018988 A3 WO 1994018988A3 EP 9400506 W EP9400506 W EP 9400506W WO 9418988 A3 WO9418988 A3 WO 9418988A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
heparins
inflammatory
immunological diseases
diseases
Prior art date
Application number
PCT/EP1994/000506
Other languages
French (fr)
Other versions
WO1994018988A2 (en
Inventor
Arnim Ulrich-Christoph Von
Original Assignee
Von Arnim Ulrich Christoph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Von Arnim Ulrich Christoph filed Critical Von Arnim Ulrich Christoph
Priority to AU62045/94A priority Critical patent/AU6204594A/en
Publication of WO1994018988A2 publication Critical patent/WO1994018988A2/en
Publication of WO1994018988A3 publication Critical patent/WO1994018988A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Abstract

A pharmaceutical for the treatment of inflammatory or immunological diseases and a method of treatment of these diseases. The invention is characterized in that the pharmaceutical comprises heparins, heparinoids, proteoglycans or low-molecular-weight heparins or a mixture thereof or a combination of low-molecular-weight heparins and Prostavasin.
PCT/EP1994/000506 1993-02-22 1994-02-22 Use of heparins for the treatment of inflammatory or immunological diseases WO1994018988A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62045/94A AU6204594A (en) 1993-02-22 1994-02-22 Use of heparins for the treatment of inflammatory or immunological diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93102750.2 1993-02-22
EP93102750 1993-02-22

Publications (2)

Publication Number Publication Date
WO1994018988A2 WO1994018988A2 (en) 1994-09-01
WO1994018988A3 true WO1994018988A3 (en) 1994-11-10

Family

ID=8212625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/000506 WO1994018988A2 (en) 1993-02-22 1994-02-22 Use of heparins for the treatment of inflammatory or immunological diseases

Country Status (3)

Country Link
AU (1) AU6204594A (en)
CA (1) CA2156735A1 (en)
WO (1) WO1994018988A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303612D0 (en) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
RU2176509C2 (en) * 1995-09-19 2001-12-10 Сейкагаку Корпорейшн Agent enhancing anti-inflammatory effect of immunodepressant (versions), method of enhancement of anti-inflammatory effect of immunodepressant, method of inflammation treatment
EP2311485A1 (en) 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 promotes wound repair
CA2475053A1 (en) * 2002-02-06 2004-04-29 Regenerx Biopharmaceuticals, Inc. Treatment of microbial infections and associated gastrointestinal disorders with thymosin .beta.4
AU2006204785B2 (en) * 2005-01-13 2010-11-25 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
EP0375976A2 (en) * 1988-12-01 1990-07-04 Hadassa Medical Organization Compounds binding to a heparin receptor as inhibitors of T cell-mediated immune reactions
WO1991012009A1 (en) * 1990-02-14 1991-08-22 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Use of suramin to treat rheumatologic diseases
WO1992019249A1 (en) * 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
EP0375976A2 (en) * 1988-12-01 1990-07-04 Hadassa Medical Organization Compounds binding to a heparin receptor as inhibitors of T cell-mediated immune reactions
WO1991012009A1 (en) * 1990-02-14 1991-08-22 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Use of suramin to treat rheumatologic diseases
WO1992019249A1 (en) * 1991-05-02 1992-11-12 Yeda Research And Development Co. Ltd. Compositions for the prevention and/or treatment of pathological processes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8935, Derwent World Patents Index; AN 89255776 *
DATABASE WPI Week 9027, Derwent World Patents Index; AN 90202467 *
DATABASE WPI Week 9135, Derwent World Patents Index; AN 91260173 *
EKRE, H-P. ET AL: "ANTI-INFLAMMATORY EFFECTS OF HEPARIN AND ITS DERIVATIVES INHIBITION OF COMPLEMENT AND OF LYMPHOCYTE MIGRATION", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 313, 1992, pages 329 - 340 *
LIDER, O. ET AL: "SUPPRESSION OF EXPERIMENTAL AUTOIMMUNE DISEASES AND PROLONGATION OF ALLOGRAFT SURVIVAL BY TREATMENT OF ANIMALS WITH LOW DOSES OF HEPARINS", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 83, no. 3, March 1989 (1989-03-01), pages 752 - 756 *

Also Published As

Publication number Publication date
AU6204594A (en) 1994-09-14
WO1994018988A2 (en) 1994-09-01
CA2156735A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
ZA949418B (en) Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
NO894296D0 (en) PROCEDURE FOR THE TREATMENT OF ARTHY AND INFLAMMATORY DISEASES.
GB9516287D0 (en) Pharmaceutical compositon
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
NO990225D0 (en) Medications for the treatment of hyperphosphatemia
AU3375693A (en) Method of the treatment of dry nose syndrome
AU1440395A (en) Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
EP0675120A3 (en) Use of ascorbyl-gamma-linolenate or a ascorbyl-dihomo-gamma-linolenate for the treatment of asthma, cancer, cardiovascular and inflammatory disorders
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
AU2807492A (en) Use of misoprostol for the treatment of allergy
AU7992994A (en) Immunoassay for the dectection of human autoantibodies
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
GB9521608D0 (en) Pharmaceutical composition
WO1994018988A3 (en) Use of heparins for the treatment of inflammatory or immunological diseases
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
AU1104392A (en) Method for the treatment of hepatic failure and disease
AU6774694A (en) Taste-masking pharmaceutical compositions and methods for making the same
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
IL105061A (en) Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1995 507315

Country of ref document: US

Date of ref document: 19950822

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2156735

Country of ref document: CA

Ref document number: 1994909021

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994909021

Country of ref document: EP

122 Ep: pct application non-entry in european phase